|
Published by: Espicom Healthcare Intelligence
Published: May. 14, 2007 - 110 Pages
Table of Contents
- Foreword
- Executive Summary
- Generic Market Overview
- Inhalation and Nasal Spray Drug Delivery
- Asthma and COPD
- Allergic rhinitis
- Influenza
- Diabetes
- Pain, Migraine and other CNS disorders
- Osteoporosis
- Anaesthesia
- Pulmonary arterial hypertension
- Nocturia
- Potential inhalation drugs for anthrax, cystic fibrosis and erectile dysfunction
- Critical Path Opportunities for Generic Drugs in the US
- Asthma & COPD
- Flixotide/Flovent (fluticasone propionate)
- Market Outlook
- Serevent (salmeterol xinafoate)
- Market Outlook
- Seretide/Advair (salmeterol xinafoate+fluticasone propionate)
- Patents
- Patent Challenge
- Safety Issues
- Market Outlook
- Pulmicort (budesonide)
- Patent Challenge
- Market Outlook
- Combivent (ipratropium bromide+salbutamol)
- Market Outlook
- Xopenex (levalbuterol)
- Patent Challenges
- Market Outlook
- Allergic rhinitis
- Flixonase (fluticasone propionate)
- Generic Competition
- Market Outlook
- Rhinocort (budesonide)
- Market Outlook
- Nasonex (mometasone furoate)
- Market Outlook
- Nasacort (triamcinolone acetonide)
- Patent Challenge
- Market Outlook
- Influenza
- Relenza (zanamivir)
- Litigation
- Market Outlook
- Migraine
- Imigran (sumatriptan)
- Patents
- Generic Competition
- Market Outlook
- Zomig (zolmitriptan)
- Patents
- Market Outlook
- Osteoporosis
- Miacalcin (calcitonin-salmon)
- Further Development
- Patents & Generic Activity
- Fortical (calcitonin-salmon [rDNA origin])
- Generic Activity
- Market Outlook
- Anaesthesia
- Ultane (sevoflurane)
- Generic Competition
- Market Outlook
- Suprane (desflurane)
- Generic Competition
- Company Profiles
- Amphastar Pharmaceuticals
- Products
- Apotex
- Inhalation and Nasal Spray Products
- Barr Pharmaceuticals
- Product Development
- Financials
- Baxter Healthcare
- Inhalation Products
- Financials
- Acquisitions
- Beximco Pharmaceuticals
- Products
- Financials
- Cipla
- Products
- Financials
- Hi-Tech Pharmacal
- Products
- Financials
- Hovione FarmaCiencia
- Products
- Financials
- Merck Generics
- Financials
- Products
- Dey
- Inhalation and Nasal Spray Products
- Financials
- Morton Grove Pharmaceuticals
- Inhalation Products
- Nephron Pharmaceuticals
- Products
- Ranbaxy Laboratories
- Products
- Financials
- Roxane Laboratories
- Products
- Financials
- RxElite
- Products
- Sandoz
- Inhalation Products
- Financials
- Teva Pharmaceutical Industries
- Products
- Asthma & COPD
- Allergic Rhinitis
- Financials
- Watson Pharmaceuticals
- Products
- Financials
- SOURCES
- Espicom Sources
- Others
- List of Tables
- Generic Pharmaceutical Expenditure in Leading Markets, 2006
- Leading Generic Drug Markets, 2006-2011 (US$ Millions)
- Population of Leading Generic Markets, 2006-2011 (000s)
- Per Capita Expenditure in Leading Generic Drug Markets, 2006-2011 (US$)
- US Patent Expiry for Major Inhalation and Nasal Spray Drugs, 2006-2017
- FDA ANDA Approvals of Inhalation and Nasal Spray Generics, 2002-2007
- FDA Tentative ANDA Approvals of Inhalation and Nasal Spray Generics, 2007
- US Patent Expiry for Major Asthma and COPD Inhalable Therapies; 2006 Sales (US$ Millions)
- US FDA Approved Generic Asthma/COPD Inhalation Products
- Flixotide/Flovent Sales, 2002-2006 (£ & US$ Million)
- Serevent Sales, 2002-2006 (£ & US$ Million)
- Seretide/Advair Sales, 2002-2006 (£ & US$ Million)
- Pulmicort Sales, 2002-2006 (US$ Million)
- Combivent Sales, 2002-2006 (EUR & US$ Million)
- Xopenex Sales, 2002-2006 (US$ Million)
- US Patent Expiry for Selected Nasal Spray Allergy Therapies; 2006 Sales (US$ Millions)
- US FDA Approved Generic Allergic Rhinitis Nasal Spray Products
- Flixonase/Flonase Sales, 2002-2006 (£ & US$ Million)
- Rhinocort Sales, 2002-2006 (US$ Million)
- Nasonex Sales, 2002-2006 (US$ Million)
- Nasacort Sales, 2002-2006 (EUR & US$ Million)
- Relenza Sales, 2005-2006 (£ & US$ Millions)
- Imigran/Imitrex Sales, 2002-2006 (£ & US$ Million)
- Zomig Sales, 2002-2006 (US$ Million)
- Miacalcic/Miacalcin Sales, 2002-2006 (US$ Million)
- Ultane/Sevorane Sales, 2003-2006 (US$ Million)
- Apotex ANDA Approvals for Inhalable and Nasal Spray Drugs, 2001-2007
- Barr Pharmaceuticals Financial Results, 2002-06 (US$ million)
- Baxter Healthcare ANDA Approvals for Inhalable Drugs, 2002
- Baxter Financial Results, 2002-2006 (US$ Million)
- Beximco Pharmaceuticals Financial Results, 2005
- Cipla Financial Results, 2003-2006
- Hi-Tech Pharmacal Fiscal Year Results, 2005-2006 (US$ millions)
- Merck Generics Financial Results, 2003-06 (EUR Millions)
- Dey ANDA Approvals, 1987-2007
- Dey Sales, 2003-2006
- Morton Grove ANDA Approval for Inhalation Products, 1999-2007
- Nephron Pharmaceuticals ANDA Approvals, 1997-2007
- Ranbaxy Financial Results, 2003-2006
- Roxane Laboratories ANDA Approvals for Inhalation and Nasal Spray Products, 2002-2007
- Roxane Net Sales, 2005-2006 (EUR & US$ Million)
- RxElite ANDA Approvals for Inhalation Products
- Sandoz ANDA Approval for Inhalation Product, 2006
- Sandoz Financial Results, 2004-06 (US$ millions)
- Teva Financial Results, 2002-2006 (US$ millions)
- Watson Financial Results, 2002-2006 (US$ Million)
- List of Figures
- Per Capita Spending on Generic Pharmaceuticals, 2006 (US$)
- Per Capita Spending on Generic Pharmaceuticals, 2011 (US$)
- Flixotide/Flovent Projected Sales, 2006-2011 (US$ Million)
- Salmeterol Xinafoate Projected Sales, 2006-2011 (US$ Million)
- Salmeterol+Fluticasone Combination Projected Sales, 2006-2011 (US$ Million)
- Pulmicort Projected Sales, 2006-2011 (US$ Million)
- Combivent Projected Sales, 2006-2011 (US$ Million)
- Levalbuterol Projected Sales, 2006-2011 (US$ Million)
- Fluticasone Propionate Nasal Spray Projected Sales, 2006-2011 (US$ Million)
- Rhinocort Projected Sales, 2006-2011 (US$ Million)
- Nasonex Projected Sales, 2006-2011 (US$ Million)
- Triamcinolone Acetonide Nasal Spray Projected Sales, 2006-2011 (US$ Million)
- Imigran/Imitrex Projected Sales, 2006-2011 (US$ Million)
- Zomig Projected Sales, 2006-2011 (US$ Million)
- Calcitonin-salmon Nasal Spray Projected Sales, 2006-2011 (US$ Million)
- Sevoflurane Projected Sales, 2006-2011 (US$ Million)
AbstractProviding…
- Product forecasts by value 2006/2011;
- Patent expiry opportunities to 2016;
- Generic market context;
- Competitive evaluation with 18 company reviews
Exciting opportunities in this high growth area can be expected over the next 10 years. At least nine significant products will lose patent protection in key markets and this number could increase depending on the outcome of patent challenges.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
